Deep vein thrombosis · participants at risk of venous thromboembolism
Combined NMES and low‐dose heparin may leads to lower total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
PE · participants at risk of venous thromboembolism
1 finding from 1 review
Total VTE · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review
All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Length of hospital stay · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Quality of life  · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Incidence of compromised microcirculation requiring invasive intervention (re‐exploration) (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes incidence of compromised microcirculation requiring invasive… compared with no LMWH (very low certainty).
1 finding from 1 review